Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2016-10-04Clinical Trial Update: Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT [NA]
A clinical trial evaluating treatment response in Non-Hodgkin lymphoma using Copper-64 labeled Rituximab PET/CT has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-07-26Clinical Trial Update: A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor [Phase 1]
A Phase 1 study of the combination of duvelisib and venetoclax in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lym…
-
CLINICAL_TRIALS withdrawal · 2016-07-14Clinical Trial Update: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies [Phase 2]
A Phase 2 clinical trial evaluating single or double donor umbilical cord blood transplant for high-risk hematologic malignancies has been w…
-
CLINICAL_TRIALS withdrawal · 2016-02-15Clinical Trial Update: Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL [Phase 2]
A Phase 2 trial evaluating a single dose of 90Y-ibritumomab tiuxetan in patients with low tumor burden, untreated or indolent non-Hodgkin ly…
-
CLINICAL_TRIALS withdrawal · 2016-02-03Clinical Trial Update: Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating a chemotherapy regimen followed by Rituximab and Yttrium-90 ibritumomab tiuxetan for AIDS-related Non-Hodgkin lymph…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-11-20Clinical Trial Update: Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors [NA]
This trial evaluating dietary and exercise interventions to prevent cardiovascular disease in young survivors of childhood cancers (brain tu…
-
CLINICAL_TRIALS withdrawal · 2015-10-12Clinical Trial Update: Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas [Phase 2]
This clinical trial update notes that the Phase 2 study of the anti-CD20 antibody ofatumumab in older patients with untreated indolent B-cel…
-
CLINICAL_TRIALS withdrawal · 2015-08-19Clinical Trial Update: Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating rituximab with dexamethasone for recurrent or refractory indolent non-Hodgkin lymphoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-08-19Clinical Trial Update: Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituxan (Rituximab) plus Cytoxan (cyclophosphamide) for indolent stage III or stage IV non-Hodgkin lymphoma has b…
-
EMA withdrawal · 2015-07-17EMA Refused: Lympreva (dasiprotimut-t) — Biovest Europe Ltd
EMA refused approval for Lympreva (dasiprotimut-t) by Biovest Europe Ltd for lymphoid malignancies.
-
CLINICAL_TRIALS withdrawal · 2015-05-06Clinical Trial Update: The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
The trial evaluating whether interim PET/CT after two cycles of chemotherapy can predict progression in non-Hodgkin lymphoma has been withdr…
-
CLINICAL_TRIALS withdrawal · 2015-04-28Clinical Trial Update: BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial of BL22 immunotoxin in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-04-17Clinical Trial Update: A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen [Phase 3]
A Phase 3 trial comparing two radioimmunotherapy regimens (I-131 tositumomab vs ibritumomab tiuxetan) for follicular and other non-Hodgkin l…
-
CLINICAL_TRIALS withdrawal · 2015-03-24Clinical Trial Update: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
This entry describes an expanded-access, multi-center, single-arm, open-label study of plerixafor for patients with non-Hodgkin's lymphoma, …
-
CLINICAL_TRIALS withdrawal · 2015-01-19Clinical Trial Update: Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma [Phase 3]
A Phase 3 trial evaluating pixantrone in combination with rituximab for indolent non-Hodgkin lymphoma was terminated.
-
CLINICAL_TRIALS withdrawal · 2014-08-13Clinical Trial Update: A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 pharmacokinetic study of ABT-199 (venetoclax) in adults with non-Hodgkin's lymphoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-05-26Clinical Trial Update: A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 [Phase 1]
Phase 1 study to assess the effect of rifampin on the metabolism of ABT-199 (venetoclax) in Non-Hodgkin lymphoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-03-05Clinical Trial Update: Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]
This Phase 1 trial evaluating donor T cells with low-dose aldesleukin and low-dose GM-CSF after donor stem cell transplant for relapsed or r…
-
CLINICAL_TRIALS withdrawal · 2013-06-06Clinical Trial Update: Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating obatoclax mesylate in combination with rituximab and bendamustine hydrochloride for relapsed or refrac…
-
CLINICAL_TRIALS withdrawal · 2012-07-30Clinical Trial Update: Rituximab Maintenance After Autologous Transplantation [Phase 3]
A Phase 3 trial evaluating rituximab maintenance after autologous transplantation in non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS withdrawal · 2012-07-09Clinical Trial Update: Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant [NA]
A clinical trial evaluating mechanical stimulation to prevent bone density loss in patients undergoing donor stem cell transplant has been w…
-
CLINICAL_TRIALS withdrawal · 2012-05-10Clinical Trial Update: Palifermin After Haploidentical PBSCT [Phase 2]
A Phase 2 trial evaluating palifermin after haploidentical peripheral blood stem cell transplantation has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-02-23Clinical Trial Update: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy [Phase 1]
Phase 1 safety study of a PD-L1 inhibitor sponsored by Bristol-Myers Squibb has been withdrawn. The study targeted hematologic malignancies …
-
CLINICAL_TRIALS withdrawal · 2010-06-11Clinical Trial Update: Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma [NA]
The clinical trial evaluating PET imaging with FDG-18 to predict response in newly diagnosed Non-Hodgkin lymphoma patients treated with ritu…
-
CLINICAL_TRIALS withdrawal · 2008-09-05Clinical Trial Update: A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma [Phase 1]
This Phase I study evaluating safety and tolerability in adults with lymphoma has been withdrawn.